Monday March 6, 2:06 pm ET
The long-standing process for Allergan Inc. as it has tried to buy out Inamed Corp. appears to be near an end.
Allergan said in a statement that it expects to receive the results of the Federal Trade Commission's review of the transaction this week.
The deal, under which Allergan will exchange for each Inamed share (NASDAQ: IMDC - News) either $84 in cash or 0.8498 share of a share of Allergan common stock (NYSE: AGN - News), at the election of the holder, has now been extended to expire March 10 at 6:00 p.m. Eastern.
As of Friday, March 3, approximately 17,779,617 shares, representing approximately 48 percent of Inamed's outstanding common stock had been tendered. The total value of the buyout bid is about $3.2 billion.
Once again, the extension was given due to antitrust regulations. Inamed must complete its divestiture of its Reloxin license, as Irvine's Allergan and Santa Barbara's Inamed make anti-wrinkle products. The Reloxin is a botulism-based product, much like Allergan's signature product, Botox.
Published March 6, 2006 by Los Angeles Business from bizjournals
The long-standing process for Allergan Inc. as it has tried to buy out Inamed Corp. appears to be near an end.
Allergan said in a statement that it expects to receive the results of the Federal Trade Commission's review of the transaction this week.
The deal, under which Allergan will exchange for each Inamed share (NASDAQ: IMDC - News) either $84 in cash or 0.8498 share of a share of Allergan common stock (NYSE: AGN - News), at the election of the holder, has now been extended to expire March 10 at 6:00 p.m. Eastern.
As of Friday, March 3, approximately 17,779,617 shares, representing approximately 48 percent of Inamed's outstanding common stock had been tendered. The total value of the buyout bid is about $3.2 billion.
Once again, the extension was given due to antitrust regulations. Inamed must complete its divestiture of its Reloxin license, as Irvine's Allergan and Santa Barbara's Inamed make anti-wrinkle products. The Reloxin is a botulism-based product, much like Allergan's signature product, Botox.
Published March 6, 2006 by Los Angeles Business from bizjournals
